The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The role of venetoclax in previously treated Waldenström’s macroglobulinemia
In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights the important role of venetoclax for patients with previously treated Waldenström’s macroglobulinemia (WM), and shares his excitement for other BCL2 inhibitors being explored in the field. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
